Bioequivalence Study of WP205 in Healthy Participants

This study is a single-center, randomized, open-label, two-period, two-sequence, single-dose, crossover bioequivalence trial conducted under fasting conditions in healthy adult volunteers. Participants will be randomized into two sequences (A and B). Each participant will receive a single intramuscular dose of the test or reference formulation according to the assigned sequence, with an adequate washout period between dosing. The primary objective of the study is to evaluate the bioequivalence of the two formulations.

NCT Number	NCT07281872
Lead Sponsor	Wanbangde Pharmaceutical Group Co., LTD
Conditions	Therapeutic Equivalency, Healthy
Enrollment	20 participants
Start Date	2025-10-29
Primary Completion	2025-11-06 (estimated)
Study Completion	2025-11-21 (estimated)
Updated on ClinicalTrials.gov	2026-08-14